Recently, several biomarkers predicting the therapy response in lung cancer have been suggested including IGFBP3 (insulin-like growth factor binding protein 3), TGM2 (transglutaminase 2), and SLFN11 (Schlafen family member 11) for cisplatin and DAPK (death-associated protein kinase) for erlotinib and cetuximab. The gene discussed is TGM2; the disease is lung cancer.